UnknownEarly Phase 1NCT05030779

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhejiang University
Principal Investigator
He Huang, PhD
First Affiliated Hospital of Zhejiang University
Intervention
Assigned Interventions CD19/BCMA CAR T-cells(biological)
Enrollment
9 enrolled
Eligibility
All sexes
Timeline
20212022

Study locations (1)

Collaborators

Yake Biotechnology Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05030779 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus

← Back to all trials